Skip to main content

Articles

Page 1 of 102

  1. Ribosomal biogenesis and ribosomal proteins have attracted attention in the context of tumor biology in recent years. Instead of being mere translational machineries, ribosomes might play an active role in tum...

    Authors: Anne-Marie Lüchtenborg, Patrick Metzger, Miguel Cosenza Contreras, Victor Oria, Martin L. Biniossek, Franziska Lindner, Klemens Fröhlich, Ambrus Malyi, Thalia Erbes, Nicole Gensch, Jochen Maurer, Andreas Thomsen, Melanie Boerries, Oliver Schilling, Martin Werner and Peter Bronsert
    Citation: Breast Cancer Research 2022 24:65
  2. Papillomas of the breast pose challenges for treatment decisions as their risk for transformation to breast cancer is low but not negligible. To spare low-risk patients the burden of substantial treatment side...

    Authors: Piotr Ziółkowski, Marta Woźniak, Ahmad Mansour, Yu An and Georg F. Weber
    Citation: Breast Cancer Research 2022 24:64
  3. Breast cancer cell lines (BCCLs) and patient-derived xenografts (PDXs) are the most frequently used models in breast cancer research. Despite their widespread usage, genome sequencing of these models is incomp...

    Authors: Niantao Deng, Andre Minoche, Kate Harvey, Meng Li, Juliane Winkler, Andrei Goga and Alex Swarbrick
    Citation: Breast Cancer Research 2022 24:63
  4. Current clinical criteria do not discriminate well between women who will or those who will not develop ipsilateral invasive breast cancer (IBC), or a DCIS recurrence after a ductal carcinoma in situ (DCIS) di...

    Authors: Olivier Loudig, Megan I. Mitchell, Iddo Z. Ben-Dov, Christina Liu and Susan Fineberg
    Citation: Breast Cancer Research 2022 24:62
  5. In clinical practice, oestrogen receptor (ER) analysis is almost entirely by immunohistochemistry (IHC). ASCO/CAP recommends cut-offs of < 1% (negative) and 1–10% (low) cells positive. There is uncertainty whe...

    Authors: Elena Lopez-Knowles, Simone Detre, Margaret Hills, Eugene F. Schuster, Maggie C. U. Cheang, Holly Tovey, Lucy S. Kilburn, Judith M. Bliss, John Robertson, Elizabeth Mallon, Anthony Skene, Abigail Evans, Ian Smith and Mitch Dowsett
    Citation: Breast Cancer Research 2022 24:61
  6. Patients with triple-negative breast cancer (TNBC) often have poorer prognosis than those with other subtypes because of its aggressive behaviors. Cancer cells are heterogeneous, and only a few highly metastat...

    Authors: Chunning Li, Teizo Yoshimura, Miao Tian, Yuze Wang, Takamasa Kondo, Ken-Ichi Yamamoto, Masayoshi Fujisawa, Toshiaki Ohara, Masakiyo Sakaguchi and Akihiro Matsukawa
    Citation: Breast Cancer Research 2022 24:60
  7. DNA methylation in blood may reflect adverse exposures accumulated over the lifetime and could therefore provide potential improvements in the prediction of cancer risk. A substantial body of research has show...

    Authors: Pierre-Antoine Dugué, Clara Bodelon, Felicia F. Chung, Hannah R. Brewer, Srikant Ambatipudi, Joshua N. Sampson, Cyrille Cuenin, Veronique Chajès, Isabelle Romieu, Giovanni Fiorito, Carlotta Sacerdote, Vittorio Krogh, Salvatore Panico, Rosario Tumino, Paolo Vineis, Silvia Polidoro…
    Citation: Breast Cancer Research 2022 24:59
  8. Higher density of stromal tumor-infiltrating lymphocytes (sTILs) at baseline has been associated with increased rates of pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) in triple-neg...

    Authors: Cornelia Kolberg-Liedtke, Friedrich Feuerhake, Madlen Garke, Matthias Christgen, Ronald Kates, Eva Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Sherko Kuemmel, Rachel Wuerstlein, Monika Graeser…
    Citation: Breast Cancer Research 2022 24:58
  9. Predictive biomarkers are needed to identify oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER + /HER2-) metastatic breast cancer (MBC) patients who would likely benefit from c...

    Authors: Cheng Liu, Shihui Hu, Xiaoping Xu, Yongping Zhang, Biyun Wang, Shaoli Song and Zhongyi Yang
    Citation: Breast Cancer Research 2022 24:57
  10. Breast cancer (BCa) has long been a health burden to women across the globe. However, the burden is not equally carried across races. Though the manifestation and behavior of BCa differs among racial groups, t...

    Authors: Shannique Clarke, Sheray N. Chin, Leah Dodds, Sophia H. L. George and Simone Badal
    Citation: Breast Cancer Research 2022 24:56
  11. Abbreviated breast MRI (abMRI) is being introduced in breast screening trials and clinical practice, particularly for women with dense breasts. Upscaling abMRI provision requires the workforce of mammogram rea...

    Authors: Lyn I. Jones, Andrea Marshall, Premkumar Elangovan, Rebecca Geach, Sadie McKeown-Keegan, Sarah Vinnicombe, Sam A. Harding, Sian Taylor-Phillips, Mark Halling-Brown, Christopher Foy, Elizabeth O’Flynn, Hesam Ghiasvand, Claire Hulme and Janet A. Dunn
    Citation: Breast Cancer Research 2022 24:55
  12. Invasive lobular breast carcinoma (ILC), the second most prevalent histological subtype of breast cancer, exhibits unique molecular features compared with the more common invasive ductal carcinoma (IDC). While...

    Authors: Sanghoon Lee and Hatice Ulku Osmanbeyoglu
    Citation: Breast Cancer Research 2022 24:54
  13. Targeting vulnerabilities of cancer cells by inhibiting key regulators of cell proliferation or survival represents a promising way to overcome resistance to current therapies. In breast cancer (BC), resistanc...

    Authors: Annamaria Salvati, Viola Melone, Assunta Sellitto, Francesca Rizzo, Roberta Tarallo, Tuula A. Nyman, Giorgio Giurato, Giovanni Nassa and Alessandro Weisz
    Citation: Breast Cancer Research 2022 24:52
  14. Deregulated signaling pathways are a hallmark feature of oncogenesis and driver of tumor progression. Dual specificity protein phosphatase 4 (DUSP4) is a critical negative regulator of the mitogen-activated pr...

    Authors: Ann Hanna, Mellissa J. Nixon, M. Valeria Estrada, Violeta Sanchez, Quanhu Sheng, Susan R. Opalenik, Abigail L. Toren, Joshua Bauer, Phillip Owens, Frank M. Mason, Rebecca S. Cook, Melinda E. Sanders, Carlos L. Arteaga and Justin M. Balko
    Citation: Breast Cancer Research 2022 24:51
  15. Authors: Courtney T. van Geelen, Peter Savas, Zhi Ling Teo, Stephen J. Luen, Chen-Fang Weng, Yi-An Ko, Keilly S. Kuykhoven, Franco Caramia, Roberto Salgado, Prudence A. Francis, Sarah-Jane Dawson, Stephen B. Fox, Andrew Fellowes and Sherene Loi
    Citation: Breast Cancer Research 2022 24:50

    The original article was published in Breast Cancer Research 2020 22:91

  16. Early age at menarche and tall stature are associated with increased breast cancer risk. We examined whether these associations were also positively associated with mammographic density, a strong marker of bre...

    Authors: Sarah V. Ward, Anya Burton, Rulla M. Tamimi, Ana Pereira, Maria Luisa Garmendia, Marina Pollan, Norman Boyd, Isabel dos-Santos-Silva, Gertraud Maskarinec, Beatriz Perez-Gomez, Celine Vachon, Hui Miao, Martín Lajous, Ruy López-Ridaura, Kimberly Bertrand, Ava Kwong…
    Citation: Breast Cancer Research 2022 24:49
  17. A pro-oxidant enzyme, NADPH oxidase 4 (Nox4) has been reported to be a critical downstream effector of TGFβ-induced myofibroblast transformation during fibrosis. While there are a small number of studies sugge...

    Authors: Shakeel Mir, Briana D. Ormsbee Golden, Brandon J. Griess, Raghupathy Vengoji, Eric Tom, Elizabeth A. Kosmacek, Rebecca E. Oberley-Deegan, Geoffrey A. Talmon, Vimla Band and Melissa LT. Teoh-Fitzgerald
    Citation: Breast Cancer Research 2022 24:48
  18. Polycyclic aromatic hydrocarbons (PAH), which are found in air pollution, have carcinogenic and endocrine disrupting properties that might increase breast cancer risk. PAH exposure might be particularly detrim...

    Authors: Rebecca D. Kehm, E. Jane Walter, Sabine Oskar, Melissa L. White, Parisa Tehranifar, Julie B. Herbstman, Frederica Perera, Lothar Lilge, Rachel L. Miller and Mary Beth Terry
    Citation: Breast Cancer Research 2022 24:47
  19. Locally advanced breast cancer (LABC), the most aggressive form of the disease, is a serious threat for women's health worldwide. The AU-rich RNA-binding factor 1 (AUF1) promotes the formation of chemo-resista...

    Authors: Taher Al-Tweigeri, Noura N. AlRaouji, Asma Tulbah, Maria Arafah, Mouad Aboussekhra, Falah Al-Mohanna, Ahmed Mostafa Gad, Abdelmonneim M. Eldali, Tusneem A. Elhassan and Abdelilah Aboussekhra
    Citation: Breast Cancer Research 2022 24:46
  20. Breast terminal duct lobular units (TDLUs), the source of most breast cancer (BC) precursors, are shaped by age-related involution, a gradual process, and postpartum involution (PPI), a dramatic inflammatory p...

    Authors: Joshua Ogony, Thomas de Bel, Derek C. Radisky, Jennifer Kachergus, E. Aubrey Thompson, Amy C. Degnim, Kathryn J. Ruddy, Tracy Hilton, Melody Stallings-Mann, Celine Vachon, Tanya L. Hoskin, Michael G. Heckman, Robert A. Vierkant, Launia J. White, Raymond M. Moore, Jodi Carter…
    Citation: Breast Cancer Research 2022 24:45
  21. Locally advanced breast cancer is a heterogeneous disease with respect to response to neoadjuvant chemotherapy (NACT) and survival. It is currently not possible to accurately predict who will benefit from the ...

    Authors: Christine Aaserød Pedersen, Maria Dung Cao, Thomas Fleischer, Morten B. Rye, Stian Knappskog, Hans Petter Eikesdal, Per Eystein Lønning, Jörg Tost, Vessela N. Kristensen, May-Britt Tessem, Guro F. Giskeødegård and Tone F. Bathen
    Citation: Breast Cancer Research 2022 24:43
  22. Obesity and adult weight gain are linked to increased breast cancer risk and poorer clinical outcomes in postmenopausal women, particularly for hormone-dependent tumors. Menopause is a time when significant we...

    Authors: Elizabeth A. Wellberg, Karen A. Corleto, L. Allyson Checkley, Sonali Jindal, Ginger Johnson, Janine A. Higgins, Sarina Obeid, Steven M. Anderson, Ann D. Thor, Pepper J. Schedin, Paul S. MacLean and Erin D. Giles
    Citation: Breast Cancer Research 2022 24:42
  23. The majority of BRCA1-mutant breast cancers are characterized by a triple-negative phenotype and a basal-like molecular subtype, associated with aggressive clinical behavior. Current treatment options are limited...

    Authors: Leonie Ratz, Chiara Brambillasca, Leandra Bartke, Maxim A. Huetzen, Jonas Goergens, Orsolya Leidecker, Ron D. Jachimowicz, Marieke van de Ven, Natalie Proost, Bjørn Siteur, Renske de Korte-Grimmerink, Peter Bouwman, Emilia M. Pulver, Roebi de Bruijn, Jörg Isensee, Tim Hucho…
    Citation: Breast Cancer Research 2022 24:41
  24. The Bcl-3 protein is an atypical member of the inhibitor of -κB family that has dual roles as a transcriptional repressor and a coactivator for dimers of NF-κB p50 and p52. Bcl-3 is expressed in mammary adenoc...

    Authors: David Carr, Aiman Zein, Josée Coulombe, Tianqi Jiang, Miguel A. Cabrita, Gwendoline Ward, Manijeh Daneshmand, Andrea Sau and M. A. Christine Pratt
    Citation: Breast Cancer Research 2022 24:40
  25. Chimeric antigen receptor (CAR)-T cells can induce powerful immune responses in patients with hematological malignancies but have had limited success against solid tumors. This is in part due to the immunosupp...

    Authors: Micaela Harrasser, Satyen Harish Gohil, Hiu Lau, Marco Della Peruta, Vincent Muczynski, Dominic Patel, Elena Miranda, Kristiana Grigoriadis, Anita Grigoriadis, David Granger, Rachel Evans and Amit Chunilal Nathwani
    Citation: Breast Cancer Research 2022 24:39
  26. The effect of extracellular microenvironment (hypoxia and pH) has been regarded as a key hallmark in cancer progression. The study aims to investigate the effects of carbonic anhydrase IX (CAIX), a key hypoxia...

    Authors: Chong Hui Clara Ong, Dong Yeul Lee, Bernett Lee, Huihua Li, Jeffrey Chun Tatt Lim, Johnathan Xiande Lim, Joe Poh Sheng Yeong, Hiu Yeung Lau, Aye Aye Thike, Puay Hoon Tan and Jabed Iqbal
    Citation: Breast Cancer Research 2022 24:38
  27. Triple negative breast cancer (TNBC) is an aggressive subtype of invasive breast cancer that disproportionately affects Black women and contributes to racial disparities in breast cancer mortality. Prior resea...

    Authors: Scott D. Siegel, Madeline M. Brooks, Shannon M. Lynch, Jennifer Sims-Mourtada, Zachary T. Schug and Frank C. Curriero
    Citation: Breast Cancer Research 2022 24:37
  28. Up to 60% of breast cancer patients treated with chemotherapy is confronted with cognitive problems, which can have a significant impact on daily activities and quality of life (QoL). We investigated whether e...

    Authors: E. W. Koevoets, S. B. Schagen, M. B. de Ruiter, M. I. Geerlings, L. Witlox, E. van der Wall, M. M. Stuiver, G. S. Sonke, M. J. Velthuis, J. J. Jobsen, M. B. E. Menke-Pluijmers, E. Göker, C. C. van der Pol, M. E. M. M. Bos, L. W. Tick, N. A. van Holsteijn…
    Citation: Breast Cancer Research 2022 24:36
  29. CCR5 is a motility chemokine receptor implicated in tumor progression, whose activation and subsequent endocytosis may identify highly aggressive breast cancer cell subtypes likely to spread into the circulato...

    Authors: Ashvathi Raghavakaimal, Massimo Cristofanilli, Cha-Mei Tang, R. K. Alpaugh, Kirby P. Gardner, Saranya Chumsri and Daniel L. Adams
    Citation: Breast Cancer Research 2022 24:35
  30. PET imaging of 18F-fluorodeoxygucose (FDG) is used widely for tumour staging and assessment of treatment response, but the biology associated with FDG uptake is still not fully elucidated. We therefore carried...

    Authors: G. P. Ralli, R. D. Carter, D. R. McGowan, W.-C. Cheng, D. Liu, E. J. Teoh, N. Patel, F. Gleeson, A. L. Harris, S. R. Lord, F. M. Buffa and J. D. Fenwick
    Citation: Breast Cancer Research 2022 24:34
  31. Breast cancer is uncommon in men and its aetiology is largely unknown, reflecting the limited size of studies thus far conducted. In general, number of children fathered has been found a risk factor inconsiste...

    Authors: Anthony J. Swerdlow, Cydney Bruce, Rosie Cooke, Penny Coulson and Michael E. Jones
    Citation: Breast Cancer Research 2022 24:29
  32. Opioid and beta-adrenergic receptors are recently shown to cross talk via formation of receptor heterodimers to control the growth and proliferation of breast cancer cells. However, the underlying cell signali...

    Authors: Bénédicte Rousseau, Sengottuvelan Murugan, Ajay Palagani and Dipak K. Sarkar
    Citation: Breast Cancer Research 2022 24:33
  33. The interferon response can influence the primary and metastatic activity of breast cancers and can interact with checkpoint immunotherapy to modulate its effects. Using N-ethyl-N-nitrosourea mutagenesis, we foun...

    Authors: Wing-Hong Jonathan Ho, Andrew M. K. Law, Etienne Masle-Farquhar, Lesley E. Castillo, Amanda Mawson, Moira K. O’Bryan, Christopher C. Goodnow, David Gallego-Ortega, Samantha R. Oakes and Christopher J. Ormandy
    Citation: Breast Cancer Research 2022 24:31
  34. Parathyroid hormone-related protein (PTHrP) is required for embryonic breast development and has important functions during lactation, when it is produced by alveolar epithelial cells and secreted into the mat...

    Authors: Diego Y. Grinman, Kata Boras-Granic, Farzin M. Takyar, Pamela Dann, Julie R. Hens, Christina Marmol, Jongwon Lee, Jungmin Choi, Lewis A. Chodosh, Martin E. Garcia Sola and John J. Wysolmerski
    Citation: Breast Cancer Research 2022 24:30
  35. Hormones impact breast tissue proliferation. Studies investigating the associations of circulating hormone levels with mammographic breast density have reported conflicting results. Due to the limited number o...

    Authors: Rachel Mintz, Mei Wang, Shuai Xu, Graham A. Colditz, Chris Markovic and Adetunji T. Toriola
    Citation: Breast Cancer Research 2022 24:28
  36. Mammographic density (MD) phenotypes, including percent density (PMD), area of dense tissue (DA), and area of non-dense tissue (NDA), are associated with breast cancer risk. Twin studies suggest that MD phenot...

    Authors: Hongjie Chen, Shaoqi Fan, Jennifer Stone, Deborah J. Thompson, Julie Douglas, Shuai Li, Christopher Scott, Manjeet K. Bolla, Qin Wang, Joe Dennis, Kyriaki Michailidou, Christopher Li, Ulrike Peters, John L. Hopper, Melissa C. Southey, Tu Nguyen-Dumont…
    Citation: Breast Cancer Research 2022 24:27
  37. Methyltransferase SETDB1 is highly expressed in breast cancer (BC), however, the mechanisms by which SETDB1 promotes BC progression to endocrine therapy resistance remains elusive. In this study, we examined t...

    Authors: Zexuan Liu, Junhao Liu, Behnam Ebrahimi, Uday P. Pratap, Yi He, Kristin A. Altwegg, Weiwei Tang, Xiaonan Li, Zhao Lai, Yidong Chen, Liangfang Shen, Gangadhara R. Sareddy, Suryavathi Viswanadhapalli, Rajeshwar R. Tekmal, Manjeet K. Rao and Ratna K. Vadlamudi
    Citation: Breast Cancer Research 2022 24:26
  38. Despite advancements in therapies, brain metastasis in patients with triple negative subtype of breast cancer remains a therapeutic challenge. Activated microglia are often observed in close proximity to, or w...

    Authors: Sok Lin Foo, Karishma Sachaphibulkij, Corinne L. Y. Lee, Gracemary L. R. Yap, Jianzhou Cui, Thiruma Arumugam and Lina H. K. Lim
    Citation: Breast Cancer Research 2022 24:25
  39. Multigene panel tests for breast cancer predisposition routinely include ATM as it is now a well-established breast cancer predisposition gene.

    Authors: Anne-Laure Renault, James G. Dowty, Jason A. Steen, Shuai Li, Ingrid M. Winship, Graham G. Giles, John L. Hopper, Melissa C. Southey and Tú Nguyen-Dumont
    Citation: Breast Cancer Research 2022 24:24
  40. PI3K signaling is frequently activated in breast cancer and is targeted by PI3K inhibitors. However, resistance of tumor cells to PI3K inhibition, often mediated by activated receptor tyrosine kinases, is comm...

    Authors: Guus J. J. E. Heynen, Kamil Lisek, Regina Vogel, Annika Wulf-Goldenberg, Joshua Alcaniz, Elodie Montaudon, Elisabetta Marangoni and Walter Birchmeier
    Citation: Breast Cancer Research 2022 24:23
  41. There is an increasing interest in HER2-low breast cancer with promising data from clinical trials using novel anti-HER2 antibody–drug conjugates. We explored the differences in clinicopathological characteris...

    Authors: Hye Sung Won, Juneyoung Ahn, Yongseon Kim, Jin Sung Kim, Jeong-Yoon Song, Hong-Kyu Kim, Jeeyeon Lee, Heung Kyu Park and Yong-Seok Kim
    Citation: Breast Cancer Research 2022 24:22
  42. We recently showed that fucosyltransferase 8 (FUT8)-mediated core fucosylation of transforming growth factor-β receptor enhances its signaling and promotes breast cancer invasion and metastasis. However, the c...

    Authors: Cheng-Fen Tu, Fu-An Li, Ling-Hui Li and Ruey-Bing Yang
    Citation: Breast Cancer Research 2022 24:21
  43. This study investigated the efficacy of radiomics to predict survival outcome for locally advanced breast cancer (LABC) patients and the association of radiomics with tumor heterogeneity and microenvironment.

    Authors: Xuanyi Wang, Tiansong Xie, Jurui Luo, Zhengrong Zhou, Xiaoli Yu and Xiaomao Guo
    Citation: Breast Cancer Research 2022 24:20
  44. While estrogen receptor (ER) positive breast tumors generally respond well to endocrine therapy (ET), up to 40% of patients will experience relapse, either while on endocrine therapy or after ET is completed. ...

    Authors: Svetlana E. Semina, Purab Pal, Nidhi S. Kansara, Rosemary J. Huggins, Elaine T. Alarid, Geoffrey L. Greene and Jonna Frasor
    Citation: Breast Cancer Research 2022 24:19
  45. Resistance to HER2-targeted therapeutics remains a significant clinical problem in HER2+ breast cancer patients with advanced disease. This may be particularly true for HER2+ patients with basal subtype diseas...

    Authors: Moqing Liu, Rebecca Smith, Tiera Liby, Kami Chiotti, Claudia S. López and James E. Korkola
    Citation: Breast Cancer Research 2022 24:18
  46. Pharmacological inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are now an established standard of care for patients with advanced hormone receptor-positive breast cancer. The canonical mechanism under...

    Authors: April C. Watt and Shom Goel
    Citation: Breast Cancer Research 2022 24:17
  47. Low specificity in current breast imaging modalities leads to increased unnecessary follow-ups and biopsies. The purpose of this study is to evaluate the efficacy of combining the quantitative parameters of hi...

    Authors: Juanjuan Gu, Redouane Ternifi, Nicholas B. Larson, Jodi M. Carter, Judy C. Boughey, Daniela L. Stan, Robert T. Fazzio, Mostafa Fatemi and Azra Alizad
    Citation: Breast Cancer Research 2022 24:16

Annual Journal Metrics